secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2023-06-07T23:59:59+00:00
Accession:  0001104659-23-068593
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec gets EU approval for Pedmarqsi to prevent cisplatin-induced hearing loss in children
--------------------------------------------------------------------------------

- European Commission granted marketing authorization for Pedmarqsi (sodium thiosulfate) for pediatric localized solid tumors.
- First and only approved therapy in EU for preventing cisplatin-induced ototoxicity; includes 8+2 years data/market protection.
- Approval based on Phase 3 trials SIOPEL 6 and COG ACCL0431; applies to all 27 EU states plus Iceland, Norway, Liechtenstein.
- PEDMARK already FDA-approved in U.S. since September 2022; Fennec expects to make Pedmarqsi available in EU soon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923068593/0001104659-23-068593-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923068593/tm2317930d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-068593

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer